Azacitidine for Injection

DRUG2 trials

Sponsors

Bioniche Pharma USA LLC, The First Affiliated Hospital of Soochow University

Conditions

Myelodysplastic SyndromeRelapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

CompletedNCT01152346

Bioniche Pharma USA LLCMyelodysplastic Syndrome

Start: 2011-04-30End: 2013-05-31Updated: 2015-01-28

Unknown Phase

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The First Affiliated Hospital of Soochow UniversityRelapsed or Refractory B-cell Non-Hodgkin Lymphoma

Start: 2022-07-01End: 2024-06-30Target: 20Updated: 2023-04-04